Vernakalant

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It functions as a atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. It is grouped under the following drug class(es): QTc-prolonging agents. Its therapeutic use is listed as antiarrhythmics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include vernakalantum9 and Vemakalant. Its PubChem CID is 9930049.

CAS No 794466-70-9
Molecular Formula C20H31NO4
Molecular Weight 349.50 g/mol
Synonyms (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol

Frequently Asked Questions